Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Probiotics  COVID-19 treatment studies for Probiotics  C19 studies: Probiotics  Probiotics   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 78% Improvement Relative Risk CPAP, day 7 78% CPAP, day 3 10% c19probiotics.com Trinchieri et al. Probiotics for COVID-19 LATE Favors probiotics Favors control
Trinchieri, 35 patient probiotics late treatment study: 78% lower mortality [p=0.28] and 78% improvement [p=0.0001] https://c19p.org/trinchieri
copied to clipboard
Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients
Trinchieri et al., Biomedicines, doi:10.3390/biomedicines10081851
1 Aug 2022    Source   PDF   Share   Tweet
Retrospective COVID-19 patients requiring CPAP, 21 treated with SLAB51 probiotics and 15 control patients, showing improved outcomes with treatment, despite significantly lower blood oxygenation at baseline in the treatment group.
The immune effects of probiotics are strain-specific.
risk of death, 77.8% lower, RR 0.22, p = 0.28, treatment 1 of 21 (4.8%), control 3 of 14 (21.4%), NNT 6.0.
risk of miscellaneous, 77.8% lower, RR 0.22, p < 0.001, treatment 4 of 21 (19.0%), control 12 of 14 (85.7%), NNT 1.5, CPAP, day 7.
risk of miscellaneous, 9.5% lower, RR 0.90, p = 0.51, treatment 19 of 21 (90.5%), control 14 of 14 (100.0%), NNT 10, CPAP, day 3.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Trinchieri et al., 1 Aug 2022, retrospective, Italy, peer-reviewed, 10 authors, study period November 2020 - March 2021.
Contact: giancarlo.ceccarelli@uniroma1.it (corresponding author), vito.trinchieri@uniroma1.it, massimiliano.marazzato@uniroma1.it, letizia.santinelli@uniroma1.it, luca.maddaloni@uniroma1.it, paolo.vassilini@uniroma1.it, claudio.mastroianni@uniroma1.it, gabriella.dettorre@uniroma1.it, francesca.lombardi@univaq.it, alessandra.piccirilli@univaq.it.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperProbioticsAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit